CapFuran® market newly appraised at £150M/year

AtoCap has recently had a market analysis conducted for CapFuran® that indicates potential peak global sales of £150M/year.

The company has successfully raised £400k towards the cost of the trial in its most recent round and is seeking to raise a further £1.2M to complete its first clinical study.

The high sales figure is not surprising given that there are approximately 150-200 million new cases of urinary tract infection per year, and about one in four of these cases will relapse. CapFuran® is designed to tackle one of the main reasons why treatment is often ineffective, and so is poised to make a big difference for patients.

Back to news index